MedTrace Logo

Food Effect Study of BMS-984923 in Healthy Older Adult Volunteers

NCT05817643 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2024-07-30

No results posted yet for this study

Summary

This project is developing a novel disease-modifying compound for Alzheimer's disease (AD).

Conditions

Interventions

DRUG

BMS-984923

Oral capsule

Sponsors & Collaborators

  • Michael J. Fox Foundation for Parkinson's Research

    collaborator OTHER

  • Allyx Therapeutics

    lead INDUSTRY

Principal Investigators

  • Stephanie Post, MD · Principal Investigator

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
50 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-01-10
Primary Completion
2023-02-27
Completion
2024-11-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05817643 on ClinicalTrials.gov